Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.

Dadashian EL, McAuley EM, Liu D, Shaffer AL 3rd, Young RM, Iyer JR, Kruhlak MJ, Staudt LM, Wiestner A, Herman SEM.

Cancer Res. 2019 Jan 15;79(2):360-371. doi: 10.1158/0008-5472.CAN-18-0781. Epub 2018 Nov 29.

PMID:
30498085
2.

Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma.

Nakagawa M, Shaffer AL 3rd, Ceribelli M, Zhang M, Wright G, Huang DW, Xiao W, Powell J, Petrus MN, Yang Y, Phelan JD, Kohlhammer H, Dubois SP, Yoo HM, Bachy E, Webster DE, Yang Y, Xu W, Yu X, Zhao H, Bryant BR, Shimono J, Ishio T, Maeda M, Green PL, Waldmann TA, Staudt LM.

Cancer Cell. 2018 Aug 13;34(2):286-297.e10. doi: 10.1016/j.ccell.2018.06.014. Epub 2018 Jul 26.

3.

A multiprotein supercomplex controlling oncogenic signalling in lymphoma.

Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, Shaffer AL 3rd, Ceribelli M, Wang JQ, Schmitz R, Nakagawa M, Bachy E, Huang DW, Ji Y, Chen L, Yang Y, Zhao H, Yu X, Xu W, Palisoc MM, Valadez RR, Davies-Hill T, Wilson WH, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza LM, Rodriguez FJ, Estephan F, Holdhoff M, Kruhlak MJ, Hewitt SM, Thomas CJ, Pittaluga S, Oellerich T, Staudt LM.

Nature. 2018 Aug;560(7718):387-391. doi: 10.1038/s41586-018-0290-0. Epub 2018 Jun 20.

4.

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM.

N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445.

5.

Corrected and Republished from: BCL11A Is a Critical Component of a Transcriptional Network That Activates RAG Expression and V(D)J Recombination.

Lee BS, Lee BK, Iyer VR, Sleckman BP, Shaffer AL 3rd, Ippolito GC, Tucker HO, Dekker JD.

Mol Cell Biol. 2017 Dec 13;38(1). pii: e00362-17. doi: 10.1128/MCB.00362-17. Print 2018 Jan 1.

6.

Retraction for Lee et al., "The BCL11A Transcription Factor Directly Activates RAG Gene Expression and V(D)J Recombination".

Lee BS, Dekker JD, Lee BK, Iyer VR, Sleckman BP, Shaffer AL 3rd, Ippolito GC, Tucker PW.

Mol Cell Biol. 2017 Oct 13;37(21). pii: e00358-17. doi: 10.1128/MCB.00358-17. Print 2017 Nov 1. No abstract available.

7.

A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Ceribelli M, Hou ZE, Kelly PN, Huang DW, Wright G, Ganapathi K, Evbuomwan MO, Pittaluga S, Shaffer AL, Marcucci G, Forman SJ, Xiao W, Guha R, Zhang X, Ferrer M, Chaperot L, Plumas J, Jaffe ES, Thomas CJ, Reizis B, Staudt LM.

Cancer Cell. 2016 Nov 14;30(5):764-778. doi: 10.1016/j.ccell.2016.10.002.

8.

Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma.

Rui L, Drennan AC, Ceribelli M, Zhu F, Wright GW, Huang DW, Xiao W, Li Y, Grindle KM, Lu L, Hodson DJ, Shaffer AL, Zhao H, Xu W, Yang Y, Staudt LM.

Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7260-E7267. Epub 2016 Oct 31.

9.

Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.

Yang Y, Kelly P, Shaffer AL 3rd, Schmitz R, Yoo HM, Liu X, Huang DW, Webster D, Young RM, Nakagawa M, Ceribelli M, Wright GW, Yang Y, Zhao H, Yu X, Xu W, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza L, Staudt LM.

Cancer Cell. 2016 Apr 11;29(4):494-507. doi: 10.1016/j.ccell.2016.03.006.

10.

Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2.

Hodson DJ, Shaffer AL, Xiao W, Wright GW, Schmitz R, Phelan JD, Yang Y, Webster DE, Rui L, Kohlhammer H, Nakagawa M, Waldmann TA, Staudt LM.

Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):E2039-46. doi: 10.1073/pnas.1600557113. Epub 2016 Mar 18.

11.

Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.

Dekker JD, Park D, Shaffer AL 3rd, Kohlhammer H, Deng W, Lee BK, Ippolito GC, Georgiou G, Iyer VR, Staudt LM, Tucker HO.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):E577-86. doi: 10.1073/pnas.1524677113. Epub 2016 Jan 19.

12.

Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.

Kelly PN, Romero DL, Yang Y, Shaffer AL 3rd, Chaudhary D, Robinson S, Miao W, Rui L, Westlin WF, Kapeller R, Staudt LM.

J Exp Med. 2015 Dec 14;212(13):2189-201. doi: 10.1084/jem.20151074. Epub 2015 Nov 30.

13.

Pillars Article: Cell Type-Specific Chromatin Structure Determines the Targeting of V(D)J Recombinase Activity In Vitro. Cell. 1996. 85: 887-897.

Stanhope-Baker P, Hudson KM, Shaffer AL, Constantinescu A, Schlissel MS.

J Immunol. 2015 Dec 1;195(11):5106-16. No abstract available.

14.

ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans.

Hathcock KS, Padilla-Nash HM, Camps J, Shin DM, Triner D, Shaffer AL 3rd, Maul RW, Steinberg SM, Gearhart PJ, Staudt LM, Morse HC 3rd, Ried T, Hodes RJ.

Blood. 2015 Nov 12;126(20):2291-301. doi: 10.1182/blood-2015-06-654749. Epub 2015 Sep 23.

15.

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM.

Nat Med. 2015 Aug;21(8):922-6. doi: 10.1038/nm.3884. Epub 2015 Jul 20.

PMID:
26193343
16.

B-cell receptor signaling in diffuse large B-cell lymphoma.

Young RM, Shaffer AL 3rd, Phelan JD, Staudt LM.

Semin Hematol. 2015 Apr;52(2):77-85. doi: 10.1053/j.seminhematol.2015.01.008. Epub 2015 Jan 15. Review.

17.

Cell-intrinsic expression of TLR9 in autoreactive B cells constrains BCR/TLR7-dependent responses.

Nündel K, Green NM, Shaffer AL, Moody KL, Busto P, Eilat D, Miyake K, Oropallo MA, Cancro MP, Marshak-Rothstein A.

J Immunol. 2015 Mar 15;194(6):2504-12. doi: 10.4049/jimmunol.1402425. Epub 2015 Feb 13.

18.

Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.

Ceribelli M, Kelly PN, Shaffer AL, Wright GW, Xiao W, Yang Y, Mathews Griner LA, Guha R, Shinn P, Keller JM, Liu D, Patel PR, Ferrer M, Joshi S, Nerle S, Sandy P, Normant E, Thomas CJ, Staudt LM.

Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11365-70. doi: 10.1073/pnas.1411701111. Epub 2014 Jul 21.

19.

B cells are not essential for Lactobacillus-mediated protection against lethal pneumovirus infection.

Percopo CM, Dyer KD, Garcia-Crespo KE, Gabryszewski SJ, Shaffer AL 3rd, Domachowske JB, Rosenberg HF.

J Immunol. 2014 Jun 1;192(11):5265-72. doi: 10.4049/jimmunol.1400087. Epub 2014 Apr 18.

20.

Dendritic cell fate is determined by BCL11A.

Ippolito GC, Dekker JD, Wang YH, Lee BK, Shaffer AL 3rd, Lin J, Wall JK, Lee BS, Staudt LM, Liu YJ, Iyer VR, Tucker HO.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):E998-1006. doi: 10.1073/pnas.1319228111. Epub 2014 Mar 3.

21.

Control of autophagic cell death by caspase-10 in multiple myeloma.

Lamy L, Ngo VN, Emre NC, Shaffer AL 3rd, Yang Y, Tian E, Nair V, Kruhlak MJ, Zingone A, Landgren O, Staudt LM.

Cancer Cell. 2013 Apr 15;23(4):435-49. doi: 10.1016/j.ccr.2013.02.017. Epub 2013 Mar 28.

22.

The BCL11A transcription factor directly activates RAG gene expression and V(D)J recombination.

Lee BS, Dekker JD, Lee BK, Iyer VR, Sleckman BP, Shaffer AL 3rd, Ippolito GC, Tucker PW.

Mol Cell Biol. 2013 May;33(9):1768-81. doi: 10.1128/MCB.00987-12. Epub 2013 Feb 25. Retraction in: Mol Cell Biol. 2017 Oct 13;37(21):null. Erratum in: Mol Cell Biol. 2017 Dec 13;38(1):. Corrected and republished in: Mol Cell Biol. 2017 Oct 16;:null.

23.

The case of the missing c-Myc.

Shaffer AL 3rd, Staudt LM.

Nat Immunol. 2012 Nov;13(11):1029-31. doi: 10.1038/ni.2455. No abstract available.

PMID:
23080195
24.

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM.

Nature. 2012 Oct 4;490(7418):116-20. doi: 10.1038/nature11378. Epub 2012 Aug 12.

25.

Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.

Huang X, Di Liberto M, Jayabalan D, Liang J, Ely S, Bretz J, Shaffer AL 3rd, Louie T, Chen I, Randolph S, Hahn WC, Staudt LM, Niesvizky R, Moore MA, Chen-Kiang S.

Blood. 2012 Aug 2;120(5):1095-106. doi: 10.1182/blood-2012-03-415984. Epub 2012 Jun 20.

26.

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.

Yang Y, Shaffer AL 3rd, Emre NC, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, Young RM, Zhao H, Yang Y, Xu W, Buggy JJ, Balasubramanian S, Mathews LA, Shinn P, Guha R, Ferrer M, Thomas C, Waldmann TA, Staudt LM.

Cancer Cell. 2012 Jun 12;21(6):723-37. doi: 10.1016/j.ccr.2012.05.024.

27.

Prostaglandin E2 suppresses antifungal immunity by inhibiting interferon regulatory factor 4 function and interleukin-17 expression in T cells.

Valdez PA, Vithayathil PJ, Janelsins BM, Shaffer AL, Williamson PR, Datta SK.

Immunity. 2012 Apr 20;36(4):668-79. doi: 10.1016/j.immuni.2012.02.013. Epub 2012 Mar 29.

28.

Pathogenesis of human B cell lymphomas.

Shaffer AL 3rd, Young RM, Staudt LM.

Annu Rev Immunol. 2012;30:565-610. doi: 10.1146/annurev-immunol-020711-075027. Epub 2012 Jan 6. Review.

PMID:
22224767
29.

Oncogenically active MYD88 mutations in human lymphoma.

Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM.

Nature. 2011 Feb 3;470(7332):115-9. doi: 10.1038/nature09671. Epub 2010 Dec 22.

30.

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.

Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT, Hurt EM, Shaffer AL, Kuehl WM, Staudt LM.

Blood. 2011 Feb 24;117(8):2396-404. doi: 10.1182/blood-2010-04-278788. Epub 2010 Dec 16.

31.

Cooperative epigenetic modulation by cancer amplicon genes.

Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Möller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Weisenburger DD, Chan WC, Gascoyne RD, Levens D, Staudt LM.

Cancer Cell. 2010 Dec 14;18(6):590-605. doi: 10.1016/j.ccr.2010.11.013.

32.

Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.

Pérez-Galán P, Mora-Jensen H, Weniger MA, Shaffer AL 3rd, Rizzatti EG, Chapman CM, Mo CC, Stennett LS, Rader C, Liu P, Raghavachari N, Stetler-Stevenson M, Yuan C, Pittaluga S, Maric I, Dunleavy KM, Wilson WH, Staudt LM, Wiestner A.

Blood. 2011 Jan 13;117(2):542-52. doi: 10.1182/blood-2010-02-269514. Epub 2010 Oct 18.

33.

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM.

Nature. 2010 Jan 7;463(7277):88-92. doi: 10.1038/nature08638.

34.

IRF4: Immunity. Malignancy! Therapy?

Shaffer AL, Emre NC, Romesser PB, Staudt LM.

Clin Cancer Res. 2009 May 1;15(9):2954-61. doi: 10.1158/1078-0432.CCR-08-1845. Epub 2009 Apr 21. Review.

35.

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.

Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5. doi: 10.1073/pnas.0804295105. Epub 2008 Sep 2.

36.

IRF4 addiction in multiple myeloma.

Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H, Zeng Y, Chen B, Epstein J, Staudt LM.

Nature. 2008 Jul 10;454(7201):226-31. doi: 10.1038/nature07064. Epub 2008 Jun 22.

37.

Repression of BCL-6 is required for the formation of human memory B cells in vitro.

Kuo TC, Shaffer AL, Haddad J Jr, Choi YS, Staudt LM, Calame K.

J Exp Med. 2007 Apr 16;204(4):819-30. Epub 2007 Apr 2.

38.

Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation.

Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H.

Immunity. 2006 Aug;25(2):225-36.

39.

CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms.

Han SS, Peng L, Chung ST, DuBois W, Maeng SH, Shaffer AL, Sporn MB, Janz S.

Mol Cancer. 2006 Jun 7;5:22.

40.

Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells.

Liu H, Ippolito GC, Wall JK, Niu T, Probst L, Lee BS, Pulford K, Banham AH, Stockwin L, Shaffer AL, Staudt LM, Das C, Dyer MJ, Tucker PW.

Mol Cancer. 2006 May 16;5:18.

41.

A library of gene expression signatures to illuminate normal and pathological lymphoid biology.

Shaffer AL, Wright G, Yang L, Powell J, Ngo V, Lamy L, Lam LT, Davis RE, Staudt LM.

Immunol Rev. 2006 Apr;210:67-85. Review.

PMID:
16623765
42.

Transformation of late passage insulin-like growth factor-I receptor null mouse embryo fibroblasts by SV40 T antigen.

Spence SL, Shaffer AL, Staudt LM, Amde S, Manney S, Terry C, Weisz K, Nissley P.

Cancer Res. 2006 Apr 15;66(8):4233-9.

43.

Molecular and cytological features of the mouse B-cell lymphoma line iMycEmu-1.

Han SS, Shaffer AL, Peng L, Chung ST, Lim JH, Maeng S, Kim JS, McNeil N, Ried T, Staudt LM, Janz S.

Mol Cancer. 2005 Nov 9;4:40.

44.

Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice.

Park SS, Shaffer AL, Kim JS, duBois W, Potter M, Staudt LM, Janz S.

Cancer Res. 2005 Sep 1;65(17):7644-52.

45.

XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation.

Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, Zhao H, Yu X, Yang L, Tan BK, Rosenwald A, Hurt EM, Petroulakis E, Sonenberg N, Yewdell JW, Calame K, Glimcher LH, Staudt LM.

Immunity. 2004 Jul;21(1):81-93.

46.

Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation.

Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame KL.

J Immunol. 2004 Jul 15;173(2):1158-65.

47.

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.

Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM.

Cancer Cell. 2004 Feb;5(2):191-9.

48.

Lymphoid malignancies: the dark side of B-cell differentiation.

Shaffer AL, Rosenwald A, Staudt LM.

Nat Rev Immunol. 2002 Dec;2(12):920-32. Review.

PMID:
12461565
49.

Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program.

Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A, Giltnane JM, Yang L, Zhao H, Calame K, Staudt LM.

Immunity. 2002 Jul;17(1):51-62.

50.

Signatures of the immune response.

Shaffer AL, Rosenwald A, Hurt EM, Giltnane JM, Lam LT, Pickeral OK, Staudt LM.

Immunity. 2001 Sep;15(3):375-85. Review.

Supplemental Content

Loading ...
Support Center